Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910373 · ClinicalTrials.gov registry record · NA
Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy
A NA study, sponsored by Abbott Nutrition.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04910373: Clinical Trial NA study, sponsored by Abbott Nutrition.
NCT04910373 is a NA study that was terminated before completion, run by Abbott Nutrition. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04910373, a NA study, was terminated before completion, sponsored by Abbott Nutrition.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled food challenge to be conducted in infants or children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.
Primary Outcome
Percent of positive food challenge reactions to the experimental formula
Interventions
- OTHER Experimental Extensively Hydrolyzed Formula
- OTHER Placebo Extensively Hydrolyzed Formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2022-02-18 |
| Phase | NA |
Why NCT04910373 stopped before completion
NCT04910373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Experimental Extensively Hydrolyzed Formula is the first listed.
NCT04910373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04910373 about?
NCT04910373 is a clinical study titled "Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy". This is a multi-center, randomized, double-blind, placebo-controlled food challenge to be conducted in infants or children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.
What is the current status of trial NCT04910373?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2022-01-25. Estimated completion is 2022-02-18.
What interventions are being tested in trial NCT04910373?
The interventions under investigation include: Experimental Extensively Hydrolyzed Formula (OTHER), Placebo Extensively Hydrolyzed Formula (OTHER).
Who is sponsoring clinical trial NCT04910373?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04910373's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI